NEW YORK (
CHANGE IN RATINGS
was downgraded at Stifel Nicolaus to hold from buy. Company will be hurt by lower gold prices, Stifel Nicolaus said.
was downgraded to hold at TheStreet Ratings.
was downgraded at Canaccord Genuity to hold. $78 price target. Company still exhibits strong fundamentals and rising market share, but has reached its valuation limit, Canaccord Genuity said.
was upgraded at Goldman Sachs to neutral from sell. $18 price target. Company can expand its margins, Goldman said.
was downgraded at Morgan Stanley to underweight from equal-weight. Price target is $58. Cuts to physician fee schedule will negatively impact future earnings, Morgan Stanley said.
was downgraded at Deutsche Bank to hold from buy. Valuation call, based on a $26 price target, Deutsche said.
was downgraded at Robert Baird to neutral from outperform. Valuation call, Baird said.
Helmerich & Payne
was downgraded at Jefferies to hold from buy. $71 price target. Industry will likely face higher CapEx budgets, Jefferies said.
was downgraded at Goldman Sachs to neutral from buy. $36 price target. Thesis will take longer to materialize than initially anticipated, Goldman said.
was upgraded to buy at TheStreet Ratings.
was downgraded at Goldman Sachs to neutral from buy. $200 price target. Key markets may face increased pressure in the coming quarters, Goldman said.
was downgraded at Goldman Sachs to neutral from buy. $500 price target. Following preannouncement, upside case increasingly challenged, Goldman said.
Intuitive Surgical was downgraded at Canaccord Genuity to hold. $444 price target. Confusion concerning contractions in ISRG's system placement business have widened disparity amongst consensus estimates, Canaccord Genuity said.
Intuitive Surgical was downgraded at JMP Securities to market perform after failing to meet second-quarter estimates. Future estimates were also lowered.
was downgraded at Deutsche Bank to sell from hold. $38 price target. Valuation call, as the company trades at a premium to its peers, Deutsche Bank said.
was downgraded at D.A. Davidson to neutral from buy. Price target is $30. Share price is within 5% of price target, and there have been no additional catalysts, D.A. Davidson said.
was upgraded at Oppenheimer to perform from underperform. Company should benefit from rising interest rates, Oppenheimer said.
was upgraded at Oppenheimer to perform from underperform. Company has a unique growth model and should benefit from higher interest rates, Oppenheimer said.
Read: The Bank Account Takeover Epidemic
was downgraded at Goldman Sachs to sell from neutral. $27 price target. Expect limited adoption of personal cloud services in the coming months, Goldman Sachs said.
was downgraded at Stifel Nicolaus to hold from buy. Company cut is sales guidance, said Stifel Nicolaus.
STOCK COMMENTS/EPS CHANGES
estimates, price target were increased at JMP Securities. Estimates were raised through 2014. Expect an upbeat analyst meeting later this week, said JMP Securities. Outperform rating and new $44 price target.
numbers were increased at Sterne Agee. Shares are now seen reaching $40. Estimates were also increased to reflect the change in forward LIBOR curve, Sterne Agee said. Neutral rating.
price target was boosted at Deutsche Bank. Shares are now seen reaching $1,010. Company appears to be firing on all cylinders, Deutsche said. Buy rating.
numbers were raised at UBS. Shares are now seen reaching $17. Estimates were increased on a fixed balance sheet. Buy rating.
numbers were raised at KeyBanc. Shares are now seen reaching $70. Estimates were also increased following upbeat meetings with management, Keybanc said. Buy rating.
>To submit a news tip, email:
and become a fan on
This article was written by a staff member of TheStreet.